Atea Pharmaceuticals, Inc. Quarterly Debt-to-equity in % from Q2 2021 to Q3 2024

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
Atea Pharmaceuticals, Inc. quarterly Debt-to-equity history and growth rate from Q2 2021 to Q3 2024.
  • Atea Pharmaceuticals, Inc. Debt-to-equity for the quarter ending September 30, 2024 was 7.76 %, a 97.3% increase year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date
Q3 2024 7.76 +3.83 +97.3% Sep 30, 2024
Q2 2024 7.02 +3.33 +90.2% Jun 30, 2024
Q1 2024 6.17 +2.17 +54.2% Mar 31, 2024
Q4 2023 4.66 +0.09 +1.97% Dec 31, 2023
Q3 2023 3.93 -1.87 -32.2% Sep 30, 2023
Q2 2023 3.69 -11.4 -75.5% Jun 30, 2023
Q1 2023 4 -20.8 -83.8% Mar 31, 2023
Q4 2022 4.57 -29.9 -86.8% Dec 31, 2022
Q3 2022 5.8 -42 -87.9% Sep 30, 2022
Q2 2022 15.1 -36.6 -70.9% Jun 30, 2022
Q1 2022 24.8 Mar 31, 2022
Q4 2021 34.5 Dec 31, 2021
Q3 2021 47.8 Sep 30, 2021
Q2 2021 51.6 Jun 30, 2021
* An asterisk sign (*) next to the value indicates that the value is likely invalid.